-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA Approves Shanghai Henlius Biotech's IND Application for Nivolumab Biosimilar HLX18 Phase 1 Trial

Reuters·12/19/2025 09:03:42

Please log in to view news